Company Overview
Who we are
Nuravax: Pioneering Effective Neurodegenerative Immunotherapies
Nuravax is spearheading the use of immunotherapies in neurodegenerative disorders. We fully recognize the widespread impact of Alzheimer’s disease and other neurodegenerative conditions on millions of patients, caregivers, and families worldwide.
Our revolutionary MultiTEP vaccine platform, built on over two decades of extensive research, was developed in collaboration with the Institute for Molecular Medicine, various universities, and the NIH.
Our revolutionary MultiTEP vaccine platform, built on over two decades of extensive research, was developed in collaboration with the Institute for Molecular Medicine, various universities, and the NIH.
MultiTEP marks a significant advance in neurological disease treatment. Our platform successfully overcomes common immunotherapy challenges and has shown encouraging results in treating elderly patients — the group often hardest hit by these conditions.
Alzheimer's disease (AD) is a major focus at Nuravax for compelling reasons:
Widespread Impact: In the United States, AD affects an estimated 7 million people, with prevalence rising sharply in older age groups — 19% among those aged 75-84 and 42% in individuals over 84.
Lack of Effective Treatments: Despite recent advances, including the approval of monoclonal antibodies, there remains a significant lack of preventive and therapeutic medications with proven efficacy in combating AD.
Complex Pathology: Despite extensive research, the exact causes of AD remain elusive. Studies consistently indicate that amyloid beta peptide (Aβ) and tau proteins play a role in its progression.
Early Onset, Late Detection: AD begins to develop in people as young as 40-50 years old, often without noticeable symptoms, hindering early detection.
Immunotherapy: An Innovative Approach to Alzheimer’s and Parkinson’s Disease Treatment
At Nuravax, we are engineering precision immunotherapies to prevent and cure Alzheimer’s and Parkinson’s diseases. Our vaccines target the body's immune response against pathological proteins associated with neurodegenerative disorders — Aβ, tau proteins, and ɑ-synuclein — to halt or reverse disease progression.
Targeted Antibody Response: Our vaccines are designed to create antibodies that actively target and reduce the harmful effects of Aβ, tau, and ɑ-synuclein.
Preventing Pathological Progression: By forming antigen-antibody complexes within the brain, our immunotherapies prevent harmful oligomers, plaques, or tangles from forming.
Eliminating Pathological Agents: Once harmful molecules are bound by antibodies, they can be neutralized, marked for degradation by the immune system, and cleared from the brain.